Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13471113 | 0.91 | SLC29A1 (0.59) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL27621467 | 0.87 | SLC29A1 (0.66) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL6758863 | 0.86 | SLC29A1 (0.61) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL6758859 | 0.86 | SLC29A1 (0.61) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL11516417 | 0.85 | ADORA2A (0.77) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL11516427 | 0.85 | ADORA2A (0.77) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL19187118 | 0.84 | PNP (0.52) | — | |
| SCHEMBL34996 | 0.83 | SLC29A1 (0.73) | SLC29A1 | |
| SCHEMBL2218888 | 0.82 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 | |
| SCHEMBL13469564 | 0.81 | ACHE (0.43) | ADORA2AADORA3ADORA1ADORA2BSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2696679-B1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9156872-B2 | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9150603-B2 | 2′-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9061041-B2 | 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061041-B2 | 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140154211-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-06-05 | — | — | US | disclosed |
| US-20140154211-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-06-05 | — | — | US | disclosed |
| WO-2012142085-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012142075-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012142093-A2 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | HCCS, NSUN2, PNP | ADORA2A 92/4885ADORA3 72/4885ADORA1 108/4885 |
| US-20140154211-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SLC29A2, SLC29A1, SLC28A2 | ADORA2A 24/4885ADORA3 31/4885ADORA1 37/4885 |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ADAR, SLC29A1, SLC28A1 | ADORA2A 11/4885ADORA3 16/4885ADORA1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.